Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database

  title={Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database},
  author={James R. Williams and David Fitzhenry and Lauren Grant and Derek C. Martyn and Douglas A. Kerr},
  journal={BMC Neurology},
  pages={160 - 160}
BackgroundInitial symptoms of amyotrophic lateral sclerosis (ALS) are often subtle and can delay diagnosis. This exploratory analysis was conducted to better characterize the pre-diagnosis pathway undertaken by patients with ALS in the US Centers for Medicare & Medicaid Services Medicare longitudinal claims database.MethodsQuarterly Medicare claims data were analyzed to determine the pre-diagnosis pathway for an ALS patient cohort that included patients aged ≥ 65 years with ≥ 2 ALS claims… 

Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?

Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with unsatisfactory treatment options. Best management and recruitment into clinical trials requires early

Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance

For newly diagnosed ALS patients in the U.S., medical costs are substantial and increase rapidly and substantially with each disability milestone.

Early Referral to an ALS Center Reduces Several Months the Diagnostic Delay: A Multicenter-Based Study

Comorbidities, familial ALS, bulbar onset, early referral to the neurologist and being studied in a referral center were associated with a shorter diagnostic delay, and the universalization of ALS Units is probably the most efficient measure to reduce the diagnostic delay.

Minimizing the Diagnostic Delay in Amyotrophic Lateral Sclerosis: The Role of Nonneurologist Practitioners

The diagnostic delay of ALS appears to be proportionately very long, sometimes longer than that observed in previous studies (because it also included the total delay to diagnostic or treatment initiation); the rapid execution of useful additional tests by the first medical doctor, often GP (with the help of a neurologist), considerably reduces the diagnostic delay.

Hastening the Diagnosis of Amyotrophic Lateral Sclerosis

Challenges still exist as to how to facilitate earlier recognition of possible ALS by primary care physicians and other nonneurologist providers and how to foster a sense of urgency among neurologists to accelerate the diagnostic process.

Amyotrophic Lateral Sclerosis: An Aging-Related Disease

It is now recognized that the definition of familial ALS can be enlarged to include family members with frontotemporal dementia considering the tight link between the two nosological entities.

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

The ATLAS study will investigate whether tofersen can delay the emergence of clinically manifest ALS, the first interventional trial in presymptomatic ALS, and has the potential to yield important insights into the design and conduct of presymPTomatic trials, identification, and monitoring of at-risk individuals, and future treatment paradigms in ALS.

Exploring the association between outcome measures to guide clinical management in patients with amyotrophic lateral sclerosis

Clinically, when the Timed Up and Go and gait velocity are no longer appropriate due to disease progression, the Gross Motor Subscale can provide insight into functional decline, and concurrent validity between objective and self-reported measures is found.



Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000

Background: In recent years, there has been a paradigm shift in the method of healthcare delivery to amyotrophic lateral sclerosis (ALS) patients with the emergence of multidisciplinary ALS clinics

Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis

Factors affecting the diagnostic delay in amyotrophic lateral sclerosis

Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review.

The Awaji criteria has a significant clinical impact allowing earlier diagnosis and clinical trial entry in ALS, and its diagnostic performance was higher than the revised El Escorial criteria.

Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities

Improved survival was seen in patients with ALS attending tertiary ALS centres, independently from all other known prognostic factors, possibly through a better implementation of supportive treatments.

Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) – a 20-year review: Can we do better?

Examination of diagnostic timelines for people suspected of having ALS/MND over a 20-year period showed that diagnostic timelines have been surprisingly consistent, suggesting that more widespread implementation of fast-track processes could potentially reduce diagnostic delays.

Prognostic factors in ALS: A critical review

A systematic review of factors related to survival in ALS revealed the rate of symptom progression was revealed to be an independent prognostic factor, and these findings have relevant implications for the design of future trials.

Multidisciplinary ALS care improves quality of life in patients with ALS

High standard of care improves mental quality-of-life in patients with ALS, and the difference was most pronounced in the domains of Social Functioning and Mental Health, and was independent of the presence of aids and appliances.

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

To examine the efficacy of riluzole in prolonging survival, and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival, four eligible randomized trials were examined.

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  • R. MillerJ. MitchellM. LyonD. Moore
  • Medicine
    Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
  • 2003
The efficacy of riluzole in prolonging survival, and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival, is examined.